For Support: +1 608-716-7539

Voximetry Chief Executive Recognized for Outstanding Business Achievement in BioHealth.

MADISON, Wis. – Voximetry, a pioneer in advanced technology to enable personalized treatments for late-stage cancer patients, announced today that its CEO, Dr. Sue Wallace received the BioForward Wisconsin 2024 Business Achievement Award. The award recognizes outstanding lifetime leadership contributing to Wisconsin’s economic development and growth. Since 2015, BioForward has been honoring outstanding scientific and business accomplishments in the biohealth sector every year.

“BioForward has continued to recognize the leadership and innovation that has brought Wisconsin to be among the top leaders in health solutions,” said Lisa Johnson, CEO of BioForward, Inc. “The passion, creativity and perseverance of Dr. Wallace embody the spirit of the award, and we’re pleased to recognize her career of outstanding business achievements.”

Dr. Wallace has been active in the Wisconsin biohealth community for over 30 years. Her work in the radiation sciences community helped transform Positron Emission Tomography (PET) imaging from a cutting-edge research tool into a cornerstone of modern medicine, and today she continues to push the boundaries of what’s possible in the fight against cancer.

Following her time with GE Healthcare, Cardinal Health, Philips Healthcare and Accuray, Dr. Wallace now serves as the CEO of Voximetry, a start-up born from the Medical Physics department at the University of Wisconsin. Together with her team, she is working to establish a new standard of care for late-stage cancer through treatment plans tailored to individual patients.

 

About Voximetry 

Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.

About WI Biohealth Tech Hub

The WI Biohealth Tech Hub is dedicated to transforming patient care through personalized medicine, while driving advances in innovation, local technology leadership, economic development, and national security. The Hub features world-leading expertise in medical physics, a diverse workforce, and a robust supply chain to meet the demands of personalized medicine, including radiopharmaceutical therapy.

About BioForward, Inc.

Founded in 1988 as the Wisconsin Biotechnology Association, BioForward initially focused on biotechnology. In 2002, the organization expanded and officially rebranded as BioForward Wisconsin in 2009. Reflecting its diverse and growing membership, BioForward introduced the term “biohealth” to better represent the wide range of specialties within WI’s thriving biohealth landscape. Through strategic networking, collaborative initiatives, and proactive advocacy, BioForward creates an environment where innovation can flourish.